Consultant and lecturer to the Duke Law School Access to Medicines course; Board Member, Medical University of South Carolina Foundation for Research and Development, WHO Consultant, Mentor and resident instigator.
Formerly Visiting Associate Professor of the Practice at Duke’s Sanford School of Public Policy, Director of the Sanford Innovation, Technology Policy project.
Julia Barnes-Weise (J.D., CLP) is a lawyer, scholar, entrepreneur and Certified Licensing Professional. Barnes-Weise is a former Director of Business Development at Glaxo Wellcome (now GSK) and has consulted for BioMatch, LLC for many years. She has decades of experience negotiating IP licenses, alliance agreements and advising companies and institutions on partnering strategies.
Acting Head, Policy and Communications
Loren Becker has nearly 15 years of experience helping global health organizations build and manage partnerships, strategies, and programs to ensure that vulnerable communities have access to life-saving innovation. She has worked with the Coalition for Epidemic Preparedness Innovations, PATH, and a broad network of product development stakeholders to address technical, logistical, and market-based issues affecting development of and access to health technologies. Loren has a Master's degree in public policy from Duke University.
Dr. Woods is the Co-Director of the Hubert-Yeargan Center for Global Health. He is a professor in the Departments of Medicine and Pathology at Duke; an adjunct professor in Epidemiology at the University of North Carolina at Chapel Hill School of Public Health; an adjunct professor in the Emerging Infections Program at the Duke-National University of Singapore Graduate Medical School. Clinically, he serves as Chief of Infectious Diseases and clinical microbiology, and hospital epidemiologist for the Durham VA Medical Center. Dr. Woods is board-certified in internal medicine, infectious diseases, and medical microbiology.
Mark Crowell is principal consultant with Academy Innovation Advisors (AIA). AIA provides strategic planning and program development advice and consulting services in the areas of innovation, engagement, entrepreneurship and translational research to universities, boards, regional and national governing and development authorities, and private industry. Most recently, Mark was the Vice President for Innovation and Economic Development at the King Abdullah University of Science and Technology (KAUST) in Saudi Arabia.
Beibei is a corporate associate at Ropes & Gray LLP, with a focus of her practices on intellectual property transactions and life sciences industry. Beibei holds a J.D. from Duke University School of Law. Before Duke, she got both her LLB and LLM in IP Law from China. She was an active member of Creative Commons China Mainland. She also interned with the PCT Division of World Intellectual Property Organization in Geneva Switzerland.
Ana Santos Rutschman
Ana Santos Rutschman is the 2016-2018 Jaharis Faculty Fellow in Health Law and Intellectual Property. Her primary research and teaching interests include intellectual property, health law, innovation policy and regulation in the life sciences. She recently consulted for the World Health Organization on the development of the Ebola and Zika vaccines. Her academic writing has appeared or is forthcoming in the UCLA Law Review, Duke Law and Technology Review, the Yale Law Journal Forum, the Annals of Health Law, the Miami Business Law Review, and the Denver Journal of International Law and Policy, among others. In 2017, she was named a Bio IP Scholar by the American Society of Law, Medicine & Ethics.
Magali Poinot, JD is Advisor to the Executive Director at Innovative Medicines Initiative. She is Responsible for providing strategic and specialist advice and confidential support to the Executive Director on the overall function and direction of the IMI Programme Office to ensure it delivers on IMI strategic objectives to Members, Associated Partners, advisory and ad hoc bodies and stakeholders etc. The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.
Katie has several years experience working in house for the Wellcome Trust in funding translational research. She has experience in drafting and negotiating a range of transactions for Wellcome – including funding a range of vaccines, drugs, diagnostics and devices, and most recently has been involved in the establishment of CARB-X (Combatting Anti-Microbial Resistant Bacteria Accelerator) and CEPI (the Coalition for Epidemic Preparedness Innovations). Katie’s primary interests are in intellectual property transactions and access. She has experience advising on a range of governance, charitable and corporate matters.
Catherine Hennings is the Director of Commercialization & Corporate Partnerships within the Vaccine Development Global Program at PATH. Ms. Hennings is a senior executive with over 20 years of experience working at the interface of research and commercialization within the life sciences industry. Throughout her career, she has focused on bringing the results of research to the public by fostering partnerships and creating pathways to commercialization. Her experience spans both the not-for-profit and for-profit sectors and includes licensing and business development, structuring and negotiating research and development partnerships, and clinical development program strategy and implementation. Ms. Hennings has Master’s degrees in both science and business.
Additional thanks to the following
Kushal is a Rhodes Scholar at Oxford, reading for an MPhil in Evidenced-based Social Intervention and Policy. Previously, he was an undergraduate studying Public Policy and Biology at Duke University. His work on the Global Health Innovation Alliances (GHIA) team has focused on alliance mapping and incentive restructuring for vaccine development.
Courtney joined GHIAA as a freshman. She graduated in 2018 with a BA in Public Policy with a concentration in Health Policy and a certificate in Markets and Management. She is currently working as a Business Analyst at Capital One in Washington, DC.
Christina joined GHIAA in 2015 as an undergraduate at Duke University. She graduated in 2018 with a dual degree in Global Health and Public Policy, and is now exploring her interest in innovation as consultant for Bain & Company in Washington, DC.
Rosa Castro is a Senior Policy Officer at the Federation of European Academies of Medicine (FEAM). She holds a PhD and Master/LL.M dual degree in Law and Economics. Dr. Castro has carried out research and managed projects in areas at the intersection of science and health policy, including intellectual property law and the biosciences. She has been a Lecturer on Intellectual Property Law and International Health Law at LUISS University in Rome, and at the University of Bologna.
The Wellcome Trust
Dhiren Thakker, Ph.D.
UNC Eshelman School of Pharmacy
Coalition for Epidemic Preparedness Innovations
General Counsel, Medicines Patent Pool
Intellectual Technology Transfer Management, Inc.
Executive Director, CARB-X